Mark Wainberg (1945-2017)

The Canadian Association for HIV Research (CAHR) extends its condolences to the family, friends and many colleagues of Dr. Mark Wainberg, whose passing comes as a shock to the HIV research community.  One of the founding members of CAHR, Dr. Wainberg was also Past-President of CAHR, a veteran leader in the fight against HIV/AIDS and well-known for his involvement in 1989 in the vastly important initial identification of lamivudine (3TC) as an antiviral drug.  A mentor to many, his ongoing commitment to the cause will be sorely missed.

 

About CAHR

With a membership of more than 1,000 researchers and others interested in HIV research, the Canadian Association for HIV Research (CAHR) is the leading organization of HIV/AIDS researchers in Canada. CAHR is the organizing body for the Annual Canadian Conference on HIV/AIDS Research (CAHR Conference).

CAHR encourages Canadian researchers to be leaders in knowledge translation and to effectively respond both to the Canadian and global HIV/AIDS epidemics. Since its founding in 1991, CAHR has promoted excellence in HIV research, including mentorship and career development of investigators entering the field.

CAHR fosters collaboration and co-operation among HIV research communities, including basic, clinical and social sciences, epidemiology and public health. CAHR also engages people living with HIV/AIDS and AIDS service organizations in ongoing dialogue and information exchange to ensure that HIV/AIDS research remains responsive to the epidemic and its stakeholders.

CAHR is a registered charity.

Contact

For more information or to make a comment, please contact us:

Canadian Association for HIV Research

440 Laurier Avenue West, Suite 200
Ottawa, Ontario K1R 7X6

1-888-374-CAHR (2247)

For conference related matters, please email conference@cahr-acrv.ca.